Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

264.02 +1.51 (+0.58%)
Official Closing Price Updated: 7:00 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
The company is still looking to bounce back after the beating it took in recent years. 
Via The Motley Fool
Topics Economy
News headline image
Is AbbVie the Best Dividend King to Buy in September? ↗
It is certainly a good Dividend King to buy in September. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dividend Stocks That Are No-Brainer Buys Right Now, Starting With This Healthcare Giant ↗
These three stocks meet multiple criteria for long-term dividend investing success. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline ↗
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s... 
Via MarketBeat
Topics ETFs
News headline image
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside ↗
Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine. 
Via The Motley Fool
News headline image
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? ↗
AbbVie's dividend is a very appealing factor. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.76%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference ↗
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a... 
Via MarketBeat
News headline image
2 Dividend Stocks Built to Hold Up When Markets Don't ↗
These two are on the Dividend Kings list. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Billionaire Israel Englander Is Doubling Down on These 2 Outstanding Dividend Stocks. Should You? ↗
Dividend seekers can hardly go wrong with these companies. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior. 
Via The Motley Fool
Topics Intellectual Property
News headline image
If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗
Low-cost index funds can be a ticket to prosperity for everyday investors. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗
Owning these dividend stocks could be a simple way to make money over the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
True Beauty Aesthetics Marks One-Year Milestone With Open House
MOUNT PLEASANT, SC - September 02, 2026 - Malissa LaRoche, PA-C, owner of True Beauty Aesthetics, is celebrating one year at the practice's current Mount Pleasant location this month, with... 
Via Press Advantage
News headline image
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal. 
Via The Motley Fool
News headline image
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio. 
Via The Motley Fool
News headline image
If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today ↗
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of... 
Via Benzinga
News headline image
Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗
His AbbVie purchase was a big move into a high-yielding dividend stock. 
Via The Motley Fool
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Electric Vehicles Stocks World Trade
News headline image
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead. ↗
AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Dividend Stocks to Buy and Never Sell ↗
Both of these healthcare leaders are Dividend Kings. 
Via The Motley Fool
Topics Economy
News headline image
The Dividend ETF That Generates Passive Income While You Sleep ↗
Income generation is more about finding consistency than finding an ultra-high yield. 
Via The Motley Fool
Topics ETFs
News headline image
3 Unpopular Stocks That Deserve Some Love
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Topics Energy
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Don't bet against Vertex Pharmaceuticals in cystic fibrosis. 
Via The Motley Fool
News headline image
Plastic Surgeon Dr. Young Cho Named to National MD Codes Faculty
August 19, 2026 - Integrated Aesthetics announced that board-certified plastic surgeon Young Cho, MD, PhD, has been selected as a national trainer in the MD Codes™ program within the Allergan... 
Via Press Advantage
News headline image
Billionaire Ken Griffin Increased His Position in This Dividend King by 547% ↗
Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.